A new study challenges the common oncology assumption that all immune checkpoint inhibitor side effects are uniformly associated with better survival. The analysis suggests survival impact varies by side-effect type. By distinguishing which adverse events correlate with outcomes, the work could refine how clinicians counsel patients and how trial safety signals are interpreted. For biotech, the findings add nuance to biomarker development that uses toxicity patterns—supporting more targeted investigations instead of treating treatment-emergent toxicity as a single category.